Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply from the authors.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Among authors: ando y. Hepatol Res. 2020 Dec;50(12):1393. doi: 10.1111/hepr.13578. Hepatol Res. 2020. PMID: 33280200 No abstract available.
A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
Kosaka Y, Kawaoka T, Aikata H, Suehiro Y, Yamaoka K, Ando Y, Namba M, Takeuchi Y, Fujii Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Kimura T, Nagata Y, Chayama K. Kosaka Y, et al. Among authors: ando y. Clin J Gastroenterol. 2020 Oct;13(5):839-843. doi: 10.1007/s12328-020-01093-9. Epub 2020 Jan 23. Clin J Gastroenterol. 2020. PMID: 31974811
Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.
Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Kodama K, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Ando Y, et al. Clin J Gastroenterol. 2020 Oct;13(5):867-872. doi: 10.1007/s12328-020-01099-3. Epub 2020 Feb 4. Clin J Gastroenterol. 2020. PMID: 32020539
Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Among authors: ando y. Hepatol Res. 2020 Jul;50(7):885-888. doi: 10.1111/hepr.13496. Epub 2020 Mar 6. Hepatol Res. 2020. PMID: 32088930
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y, Kawaoka T, Suehiro Y, Yamaoka K, Kosaka Y, Uchikawa S, Kodama K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Azakami T, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Oncology. 2020;98(11):787-797. doi: 10.1159/000509387. Epub 2020 Sep 3. Oncology. 2020. PMID: 32882687
Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
Yamaoka K, Kodama K, Hiramatsu A, Ando Y, Kosaka Y, Suehiro Y, Fujii Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Takahashi S, Chayama K, Aikata H. Yamaoka K, et al. Among authors: ando y. J Gastroenterol Hepatol. 2021 Jun;36(6):1685-1693. doi: 10.1111/jgh.15377. Epub 2021 Jan 6. J Gastroenterol Hepatol. 2021. PMID: 33326154
A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system.
Yoshikawa Y, Imamura M, Morio K, Yamaoka K, Ando Y, Kosaka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Wakita T, Katano H, Chayama K. Yoshikawa Y, et al. Among authors: ando y. IDCases. 2021 Jan 27;23:e01059. doi: 10.1016/j.idcr.2021.e01059. eCollection 2021. IDCases. 2021. PMID: 33552903 Free PMC article.
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Amioka K, Kawaoka T, Ogawa Y, Kikukawa C, Naruto K, Yoshikawa Y, Ando Y, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Fukuhara T, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Chayama K, Aikata H. Amioka K, et al. Among authors: ando y. Oncology. 2021;99(5):327-335. doi: 10.1159/000514315. Epub 2021 Mar 5. Oncology. 2021. PMID: 33677453
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y, Kawaoka T, Amioka K, Naruto K, Ogawa Y, Yoshikawa Y, Kikukawa C, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Oncology. 2021;99(8):507-517. doi: 10.1159/000515865. Epub 2021 May 4. Oncology. 2021. PMID: 33946070
2,824 results